{"brief_title": "Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea", "brief_summary": "The purpose of the study is to assess the safety and efficacy of FK614 in type 2 diabetic subjects receiving sulfonylurea (SU) monotherapy.", "detailed_description": "This is a prospective randomized, double-blind, placebo controlled, parallel group, Phase 2 study. Subjects meeting selection criteria will be randomly assigned to receive 12 weeks twice daily (BID) dosing with FK614 or placebo. Enrollment for this study will be approximately 200 patients.", "condition": ["Diabetes Mellitus"], "intervention_type": ["Drug"], "intervention_name": ["FK614"], "criteria": "Inclusion Criteria - Has history of type 2 diabetes mellitus for at least 1 year - Has been taking current sulfonylurea (SU) for at least 3 months. Subjects currently taking metformin may be eligible to be switched. - Has not received any oral antidiabetic medication other than an SU or taken regularly prescribed insulin for at least 3 months Exclusion Criteria - Has type 1 diabetes mellitus - Has uncontrolled hypertension, i.e., systolic BP >170 or diastolic BP > 95 mm Hg. - History of congestive heart failure", "gender": "All", "minimum_age": "25 Years", "maximum_age": "70 Years", "healthy_volunteers": "No", "mesh_term": ["Diabetes Mellitus"], "id": "NCT00036192"}